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The metabolic syndrome refers to a well defined group of risk factors, including central obesity and inflammation, for the devel-
opment of diabetes and cardiovascular disease. Interestingly, many studies have recently led to the emergence of somewhat un-
expected relationships between several infectious diseases and various aspects of the metabolic syndrome. Our understanding of 
the mechanisms underlying these interactions is also rapidly developing and some of these are summarized in this article. We 
will focus first on bacterial infection, and most notably the role of gut microbiota in regulaton of both obesity and inflammation. 
In particular, we focus on the role of inflammasomes and propose that understanding the role of Toll-like receptors and Nod-like 
receptors in the pathogenesis of inflammatory disorders with or without infection may provide novel targets for prevention and/
or treatment of associated diseases. Secondly, chronic bacterial or viral infection and emerging links with metabolism will be re-
viewed. Finally, consideratons of biomarkers for metabolic syndrome, in particular lipocalin-2, and their link with infection will 
be discussed.
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The metabolic syndrome describes a cluster of risk factors for 
the development of diabetes and cardiovascular disease. The 
latest clinical definition of the metabolic syndrome by the In-
ternational Diabetes Federation and the American Heart As-
sociation/National Heart, Lung, and Blood Institute [1] states 
that three abnormal findings in the following five would quali-
fy a person as having the metabolic syndrome – raised blood 
pressure, atherogenic dyslipidemia, raised triglycerides, low 
high density lipoprotein cholesterol (HDL-C), dysglycemia, 
and central obesity (excessive fat tissue in and around the ab-
domen). Of course the prognosis afforded by these consider-
ations is not absolute since additional factors such as age, gen-
der and lifestyle (e.g., smoking, level of exercise) contribute to 
absolute risk. The prevalence of the metabolic syndrome has 
increased steadily worldwide and in the United States an esti-
mated 50 million Americans fall in this category. Associated 
with this is clearly a profound impact on morbidity and mor-
tality.
METABOLIC SYNDROME AND INFECTION
Obesity and the metabolic syndrome are associated with a 
proinflammatory state [2], often defined by elevated circulat-
ing C-reactive protein. Studies on the central role of inflam-
mation have recently unearthed many rather unexpected 
nodes of interaction with various infectious diseases, previ-
ously thought to be unrelated to metabolic syndrome (Fig. 1). 
For example, there are now clear interactions in particular be-
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groups known as the Firmicutes and the Bacteroidetes and the 
relative proportion of these two phyla may protect or predis-
pose the host to obesity [5]. Metagenomic studies demonstrat-
ed that the proportion of Firmicutes is higher in obese individ-
uals as compared to lean controls and this correlates with a 
higher number of genes encoding enzymes that break down 
otherwise indigestible dietary polysaccharides, more fermen-
tation end products and fewer calories remaining in the faeces 
of obese individuals. Intriguingly, microbiota transplantation 
studies in germ-free murine models showed that the efficient 
energy extraction traits of obese-type gut flora are transmissi-
ble [6,7]. Although such experiments are an extreme example 
they clearly show that obesity has ‘infectious’ characteristics. 
Collectively these observations indicate that differences in the 
efficiency of caloric extraction from food may be determined 
by the composition of the microbiota, which, in turn, may 
contribute to differential body weights. Another mechanism 
by which the microbiome may contribute to metabolic disor-
ders is via triggering systemic inflammation, as described be-
low.
GUT MICROBIOTA AND ROLE IN REGULATION OF 
SYSTEMIC INFLAMMATION
The gastrointestinal tract of a normal fetus is sterile. During 
tween gut microbiota as well as chronic bacterial or viral in-
fection and various aspects of the metabolic syndrome such as 
obesity and inflammation. Our understanding of the mecha-
nisms underlying these interactions is also rapidly developing 
and recent data and potential future studies are described in 
more detail below.
GUT MICROBIOTA AND ROLE IN REGULATION OF 
OBESITY
The human gut is populated by at least 10
13 microorganisms, 
mostly anaerobic bacteria, generally known as the microbiota. 
The metabolic activities of these microbes are comparable to 
an ‘organ’ particularly adapted to human physiology and exe-
cuting vital functions including the ability to process other-
wise indigestible nutrients, repressing the growth of harmful 
microorganisms and training the immune system to respond 
only to pathogens [3]. In recent years it became evident that 
the gut microbiota constitutes an important node for integrat-
ing environmental factors and metabolic processes in the host, 
including energy extraction from nutrients and fat storage. 
This suggested the relatively new concept of a possible role in 
obesity and, consequently, other aspects of the metabolic syn-
drome [4]. The two predominant populations of microbiota in 
both rodent and human gut are members of the bacterial 
Fig. 1. Integration of various inputs in development of metabolic syndrome. TLRs, Toll-like receptors; NLRs, Nod-like receptors.73
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birth and rapidly thereafter, bacteria from the mother and the 
surrounding environment colonize the infant’s gut. As a conse-
quence, the immune system coevolves with the microbiota dur-
ing postnatal life, which allows the host and microbiota to coex-
ist in a mutually beneficial relationship. In particular the innate 
immune system, long-appreciated for its role in defending 
against infection by pathogenic microbes, has emerged as a key 
regulator of the gut microbiota. Innate immune recognition of 
microbe-associated molecular patterns by multiple families of 
pattern-recognition molecules such as Toll-like receptors 
(TLRs) and Nod-like receptors (NLRs) instructs the innate and 
adaptive immune system to protect the host from pathogens 
while also acting to establish a beneficial mutualism with com-
mensal organisms[8,9]. Therefore, molecular integration of nu-
trient- and pathogen sensing pathways became of great interest 
in understanding the mechanisms of insulin resistance, type 2 
diabetes (T2D), and other chronic metabolic pathologies.
Cellular factors linking infection and metabolism: TLRs
Recent findings indicate that TLRs, which are up-regulated in 
the affected tissue of most inflammatory disorders, can medi-
ate crosstalk between the immune systems and whole body 
metabolism [10]. TLR’s are a major form of cell surface innate 
immune sensor and their activation induces the recruitment 
of cells such as macrophages and neutrophils [11]. It has been 
demonstrated that TLR4, a sensor for lipopolysaccharides on 
Gram-negative bacteria, is involved in the induction of proin-
flammatory cytokine expression in macrophages, adipocytes 
and liver [12]. TLR4 is also activated in response to free fatty 
acids, which are known to play a key role in the etiology of in-
sulin resistance. Importantly, mice genetically deficient for 
TLR4 are substantially protected from the ability of systemic 
lipid infusion to suppress insulin signaling in muscle and re-
duce insulin-mediated changes in systemic glucose metabo-
lism [12]. Similarly, it was recently reported that mice geneti-
cally deficient in TLR5, which recognizes flagellin (the protein 
monomer that makes up the filament of bacterial flagella, 
found on nearly all motile bacteria) exhibit hyperphagia and 
develop hallmark features of metabolic syndrome, including 
hyperlipidemia, hypertension, insulin resistance, and in-
creased adiposity [13]. While the underlying molecular mech-
anisms remain to be defined, it is tempting to speculate that 
loss of TLR5 produces alterations in the gut microbiota that 
induce low-grade inflammatory signaling. This signaling may 
in turn decrease insulin sensitivity, induce hyperphagia, and 
ultimately initiate development of various other aspects of 
metabolic syndrome.
Cellular factors linking infection and metabolism: NLRs
NLR signaling results in the formation of large molecular scaf-
fold complexes with multiple components (termed an inflam-
masome) which are intricately linked with inflammation and 
crosstalk with TLR-mediated signaling events [11]. NLR fami-
ly inflammasomes have emerged as central platforms of innate 
immunity that link the sensing of infectious agents and meta-
bolic stress to the activation of pro-inflammatory cytokines 
such as interleukin (IL)-1B and IL-18. Inflammasomes do not 
regulate transcription of immune response genes but instead 
activate caspase-1, an integral component of the inflammasome 
and proteolytic enzyme that cleaves and activates these secret-
ed cytokines [14]. Currently the most fully characterized in-
flammasome, the NLRP3 inflammasome consists of the NLRP3 
scaffold, the ASC (PYCARD) adaptor, and caspase-1, which is 
activated upon a number of diverse stimuli and dysregulated 
in various diseases [15]. Thus, coordinated inputs from TLR 
(gene transcription) and NLR (processing) are often needed 
for full activation of one of the most important proinflamma-
tory cytokines, IL-1B [16]. 
  Additional functions of NLR inflammasomes continue to 
emerge. Inflammasomes regulate pyroptosis, a caspase-1-de-
pendent form of cell death that itself is highly inflammatory 
[17]. Intriguingly, the NLRP3 inflammasome also detects signs 
of metabolic stress, including elevated extracellular glucose 
[18], Thus, it has been demonstrated that NLRP3 interacts with 
thioredoxin (TRX)-interacting protein (TXNIP), a protein 
linked to insulin resistance. TXNIP deficiency impaired activa-
tion of the NLRP3 inflammasome and subsequent activation of 
IL-1B [15]. It is established that IL-1B plays an important role 
in mediating the toxic effects of prolonged hyperglycaemia 
(glucotoxicity) in pancreatic islets, driving B cell destruction 
and dysregulating glucose-stimulated insulin secretion [19]. 
Thus, it is important to note that mice genetically deficient for 
both TXNIP and NLRP3 showed impaired glucose homeosta-
sis, providing further evidence for a mechanistic link between 
IL-1B in the pathogenesis of diabetes [15]. The therapeutic po-
tential of targeting the mechanisms outlined above are rein-
forced by the recent promise of IL-1B receptor antagonism in 
clinical trials for the treatment of diabetes [20,21].74
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CHRONIC BACTERIAL OR VIRAL 
INFECTION
As activation of inflammasomes emerges as a central event in 
sensing exogenous and endogenous danger signals, it appears 
also worthwhile to reconsider aspects of metabolic dysfunc-
tion with concurrent chronic infection. It is also conceivable 
that chronic bacterial and viral infections trigger pro-inflam-
matory signals, which may induce metabolic pathologies. For 
example, there is evidence that individuals infected with mul-
tiple pathogens such as HSV-1, HSV-2, CMV, Helicobacter 
pylori, and hepatitis A have high C-reactive protein levels, in-
dicating enhanced inflammation [22]. These individuals also 
had an elevated relative risk for coronary artery disease. A 
cross-sectional population-based study reported a significant 
positive correlation of various parameters defining the meta-
bolic syndrome and chronic infection with Chlamydia pneu-
moniae, Helicobacter pylori, CMV and HSV-1 [23]. Moreover, 
human immunodeficiency virus (HIV)-infected patients de-
velop multiple metabolic abnormalities including insulin re-
sistance, lipodystrophy and dyslipidemia. Although this is of-
ten attributed to therapy, it is now clear that lipid and glucose 
abnormalities are apparent in HIV-infected patients even be-
fore commencing highly active antiretroviral therapy (HAART) 
[24]. Another striking example is the hepatitis C virus (HCV), 
which induces inflammation via several mechanisms and ulti-
mately leads to insulin resistance, steatosis, fibrosis, apoptosis 
and hepatocellular carcinoma. Proteomic data suggest that 
HCV induces early perturbations in glycolysis, the pentose 
phosphate pathway, and the citric acid cycle, which favor host 
biosynthetic activities supporting viral replication and propa-
gation. This is followed by a compensatory shift in metabolism 
aimed at maintaining energy homeostasis and cell viability 
during elevated viral replication and increasing cellular stress 
[25]. With emerging insight into the pathogenic mechanisms 
leading to insulin resistance in infected individuals, HCV is 
now regarded as a cause of metabolic syndrome-like out-
comes, as opposed to simple viral infection [26]. In a similar 
fashion, recent evidence demonstrated that HIV replication in 
human T-cells, without any influence of antiviral drugs or other 
factors, can stimulate production of novel cellular enzymes 
and proteins that enhance fatty acid synthesis, increase quan-
tity of low density lipoproteins, secrete triglycerides, dysregu-
late lipid transport, oxidize lipids, and alter lipid metabolism 
and therefore may directly impact on lipid synthesis, transport 
and metabolism [27]. Thus, significant attention is presently 
being drawn toward the integration of nutrient- and patho-
gen-sensing pathways and this should provide fertile ground 
for future mechanistic research and translation of such studies 
to novel urgently needed therapeutic strategies.
CIRCULATING BIOMARKERS LINKING 
INFECTION AND METABOLISM: 
LIPOCALIN-2
How can the information described above be integrated with 
currently used or proposed markers for metabolic syndrome? 
Many biomarkers have potential merits such as high sensitivi-
ty C-reactive protein as an overall marker of inflammation, IL-
1B as a final mediator of many detrimental effects on various 
tissues, and the oligomeric forms of adiponectin as an indica-
tor of metabolic, cardiovascular and perhaps even infectious 
status [26,28-30]. Another particularly interesting example is 
lipocalin-2, a proinflammatory adipokine which is typically 
up-regulated in obese subjects and causally involved in the de-
velopment of obesity-associated insulin resistance and meta-
bolic abnormalities [31]. It now also appears that there are sev-
eral emerging links between lipocalin-2 and infectious disease. 
Patients infected with HIV have been shown to have lower cir-
culating lipocalin-2 levels which were restored by HAART 
[32]. Lipocalin-2 knockout mice are highly susceptible to bac-
erial infection [33]. This is associated with the fact that lipoc-
alin-2 binds bacterial enterobactin siderophores to limit bac-
terial iron acquisition. Another critical component of lipocal-
in-2 action appears to be related with its endocytosis and tar-
geting, along with binding partners including bacteria, to lyso-
somes for degradation [34]. It is known that as part of the 
acute phase response to infection, TLR activation induces pro-
duction of lipocalin-2 and that treatment of adipocytes or mac-
rophages with LPS, IL-1B or additional inflammatory stimuli 
which activate NFkB results in a dramatic enhancement of li-
pocalin-2 production [35,36]. We suggest that studies on the 
use of lipocalin-2 as a biomarker for metabolic disease are 
promising but must be cogniscant of the coexistence of any in-
fection, acute or chronic, in each patient.
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